30 November 2018 - Uptravi now funded for the majority of Canadians with pulmonary arterial hypertension, but other treatments remain out of reach -

At the end of a successful Pulmonary Hypertension Awareness Month, members of the Pulmonary Hypertension Association of Canada and Scleroderma Canada have come together to thank provincial governments for providing the majority of Canadians with public funding for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH). In the past month, both British Columbia and Nova Scotia have approved Uptravi for public funding for eligible patients, making this novel therapy now accessible in nine out of 10 provinces. 

This result stems from the conclusion of pricing negotiations for Uptravi by the pan-Canadian Pharmaceutical Alliance (pCPA) in December 2017. The PAH and scleroderma communities are relieved that Canadian PAH specialists are now able to provide optimal, individualised treatment to improve the outcomes for patients living with this potentially fatal disease.

Read Pulmonary Hypertension Association of Canada press release